RU2314124C2 - Method for reimmunizing far north children against german measles - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: method involves forming group of 6 or more years old children leaving Far North regions. Rudivax vaccine is administered to these children not later than 60 days before departure. Another children group, arriving to Far North regions from other climate regions, is vaccinated not earlier than in 70 days after their arrival.

EFFECT: enhanced effectiveness of vaccination.

Description

The invention relates to medicine, in particular to immunology, and for the vaccination of rubella in the Far North.

To revaccinate children against rubella, they use the Rudivax vaccination method for all children aged 6 years [Ministry of Health of the Russian Federation. The new calendar of vaccinations in Russia. Order No. 229. - M .: 06/20/2001].

The known method does not take into account the characteristics of the formation of immunity in children in the Far North. According to this method, all 6-year-old children are vaccinated in the Far North, regardless of the length of the period of time, both before their departure to other regions and after their arrival in the Far North from other regions. A change in the region of residence, even temporary, leads to a disruption in the process of the child’s addiction to the conditions of the Far North. This is especially true for children of the Far North who often travel to other climatic zones, as well as for new arrivals. The formation of immunity in the body of children during revaccination in the Far North occurs already in the first hours after vaccination, but is completely completed after a longer time than in mid-latitudes, where 4 weeks are enough. This determines the low efficiency of revaccination and, accordingly, increases the likelihood of rubella. Vaccination according to a known method in the Far North provides for significant material and labor costs for re-vaccination.

The objective of the present invention is to increase the effectiveness of revaccination and reduce material and labor costs for revaccination against rubella among children living in the Far North and over 6 years of age.

The essence of the invention lies in the fact that among children living in the Far North and having reached 6 years of age, according to the invention, a group of people leaving the Far North is formed and vaccinated with Rudivax vaccine no later than 60 days before departure. They also form a group of returning children and vaccinate them no earlier than 70 days after arriving in the Far North from other climatic zones.

The method is as follows.

In areas of the Far North, when compiling a schedule of vaccination against rubella among children over 6 years of age, data is collected on the dates of their likely departure to other climatic zones and their return to the Far North. Of the children to be revaccinated, a group of departing and a group of returning are formed. Rudivax vaccine is administered to members of the group of travelers no later than 60 days before departure to other climatic zones. Children from the group returning after returning to the Far North receive the Rudivax vaccine no earlier than 70 days after arrival.

The method can be demonstrated in the following examples.

Example 1. Soloviev S. (age 6 years). Included in the group of travelers. Vaccinated with Rudivax vaccine 40 days before leaving the Far North region. One year after revaccination, anti-rubella antibodies were not detected (ΔOP <0.208). Serum is seronegative. Vaccination is ineffective.

Example 2. Birch O. (age 6.5 years). Included in the group of travelers. Vaccinated with Rudivax vaccine 50 days before leaving the Far North region. One year after revaccination, anti-rubella antibodies were not detected (ΔOP <0.208). Serum is seronegative. Vaccination is ineffective.

Example 3. Sotnikov B. (age 6.5 years). Included in the group of travelers. Vaccinated with Rudivax vaccine 55 days before leaving the Far North region. One year after revaccination, anti-rubella antibodies were not detected (ΔOP <0.208). Serum is seronegative. Vaccination is ineffective.

Example 4. Dubyanskaya E. (age 6 years). Included in the group of travelers. Vaccinated with Rudivax vaccine 60 days before departure from the Far North regions. One year after revaccination, anti-rubella antibodies were detected in protective titers (ΔOP = 1.27). Vaccination is effective.

Example 5. Denisyuk L. (age 6.5 years). Included in the returning group. Vaccinated with Rudivax vaccine 40 days after arrival in the Far North. One year after revaccination, anti-rubella antibodies were not detected (ΔOP <0.208). Serum is seronegative. Vaccination is ineffective.

Example 6. Vasilevskaya L. (age 6 years). Included in the returning group. Vaccinated with Rudivax vaccine 50 days after arrival in the Far North. One year after revaccination, anti-rubella antibodies were not detected (ΔOP <0.208). Serum is seronegative. Vaccination is ineffective.

Example 7. Khokhlov A. (age 6.5 years). Included in the returning group. Vaccinated with Rudivax vaccine 60 days after arrival in the Far North. One year after revaccination, anti-rubella antibodies were not detected (ΔOP <0.208). Serum is seronegative. Vaccination is ineffective.

Example 8. Zadonskaya N. (age 6 years). Included in the returning group. Vaccinated with Rudivax vaccine 65 days after arrival in the Far North. One year after revaccination, anti-rubella antibodies were not detected (ΔOP <0.208). Serum is seronegative. Vaccination is ineffective.

Example 9. Shvaikovsky S. (age 6 years). Included in the returning group. Vaccinated with Rudivax vaccine 70 days after arrival in the Far North. One year after revaccination, anti-rubella antibodies were detected in protective titers (ΔOP = 1.09). Vaccination is effective.

In total, in the conditions of the Far North, 482 children were vaccinated according to the proposed method. An immunological examination (determination of anti-rubella antibodies), carried out after 1 year, showed that the most effective vaccination against rubella was obtained at the declared time, namely not later than 60 days before departure and not earlier than 70 days after arrival in the Far North.

Rubella virus antibodies were determined by enzyme immunoassay. At an average optical density of ΔOP <0.208, the studied sera were considered seronegative (there are no anti-rubella antibodies) - the vaccine is ineffective; when ΔOP in the range of 0.209-0.416 in the studied sera, anti-rubella antibodies were determined in low titers - the vaccine is effective; when ΔOP in the range of 0.417-1.08 in the studied sera, anti-rubella antibodies were determined in medium titers - the vaccine is effective; at ΔOP> 1.09 in the studied sera, anti-rubella antibodies were determined in high titers - the vaccine is effective.

Compliance with the proposed time intervals allows to increase the effectiveness of immunization against rubella in the Far North by creating favorable conditions for the formation of immunity in children when changing latitudinal zones.

Claims (1)

A method for revaccinating children against rubella in the Far North, which consists in administering the Rudivax vaccine to children over 6 years of age, characterized in that they form a group of children leaving the Far North and vaccinate them no later than 60 days before departure, and a group of children returning from other regions and vaccinate them no earlier than 70 days after arrival.